Refsum N, Arnesen H, Gilhuus-Moe C C, Godal H C
Scand J Haematol. 1977 Apr;18(4):333-6. doi: 10.1111/j.1600-0609.1977.tb01204.x.
Normotest (sample volume: 25 micronl) and Thrombotest were performed in parallel on 150 consecutive capillary blood samples from patients on long term oral anticoagulant therapy. The ratio of Normotest to Thrombotest decreased from 2.50 at a Thrombotest level of 5-5.5% to 1.95 at a Thrombotest level of 13-13.5%, indicating that the effects of PIVKA were more pronounced at lower levels of coagulation activity. The influence of varying sensitivity of the thromboplastin reagents to PIVKA is discussed. The therapeutic range of Thrombotest (5-10%) corresponded to a Normotest level of 12-20%.
对150例长期接受口服抗凝治疗患者的连续毛细血管血样本同时进行了正常凝血试验（样本量：25微升）和凝血酶试验。正常凝血试验与凝血酶试验的比值从凝血酶试验水平为5 - 5.5%时的2.50降至凝血酶试验水平为13 - 13.5%时的1.95，表明在较低凝血活性水平下，异常凝血酶原（PIVKA）的作用更为明显。文中讨论了凝血活酶试剂对PIVKA敏感性差异的影响。凝血酶试验的治疗范围（5 - 10%）对应正常凝血试验水平为12 - 20%。
